CLOROX CO /DE/, 10-Q filed on 4/30/2026
Quarterly Report
v3.26.1
Cover Page - shares
 9 Months Ended
Mar. 31, 2026
Apr. 16, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2026  
Document Transition Report false  
Entity File Number 1-07151  
Entity Registrant Name THE CLOROX COMPANY  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 31-0595760  
Entity Address, Address Line One 1221 Broadway  
Entity Address, City or Town Oakland  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94612-1888  
City Area Code 510  
Local Phone Number 271-7000  
Title of 12(b) Security Common Stock - $1.00 par value  
Trading Symbol CLX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   120,921,351
Entity Central Index Key 0000021076  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2026  
v3.26.1
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]        
Net sales $ 1,670 $ 1,668 $ 4,772 $ 5,116
Cost of products sold 948 924 2,732 2,827
Gross profit 722 744 2,040 2,289
Selling and administrative expenses 229 267 768 828
Advertising costs 177 207 533 599
Research and development costs 27 27 84 89
Loss on divestiture 0 0 0 118
Interest expense 27 23 75 66
Other (income) expense, net 6 (34) 2 (79)
Earnings before income taxes 256 254 578 668
Income tax expense 65 63 144 180
Net earnings 191 191 434 488
Less: Net earnings attributable to noncontrolling interests 4 5 10 10
Net earnings attributable to Clorox $ 187 $ 186 $ 424 $ 478
Net earnings per share attributable to Clorox        
Basic net earnings per share (in dollars per share) $ 1.54 $ 1.51 $ 3.48 $ 3.87
Diluted net earnings per share (in dollars per share) $ 1.54 $ 1.50 $ 3.47 $ 3.84
Weighted average shares outstanding (in thousands)        
Basic (in shares) 121,363 123,367 121,865 123,643
Diluted (in shares) 121,787 124,066 122,240 124,468
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2026
Jun. 30, 2025
Current assets    
Cash and cash equivalents $ 1,187 $ 167
Receivables, net 671 821
Inventories, net 588 523
Prepaid expenses and other current assets 205 97
Total current assets 2,651 1,608
Property, plant and equipment, net of accumulated depreciation and amortization of $3,044 and $2,911, respectively 1,235 1,267
Operating lease right-of-use assets 355 333
Goodwill 1,229 1,229
Trademarks, net 502 502
Other intangible assets, net 49 64
Other assets 415 558
Total assets 6,436 5,561
Current liabilities    
Notes and loans payable 1,591 4
Current operating lease liabilities 85 87
Accounts payable and accrued liabilities 1,479 1,828
Total current liabilities 3,155 1,919
Long-term debt 2,487 2,484
Long-term operating lease liabilities 323 305
Other liabilities 356 351
Deferred income taxes 23 20
Total liabilities 6,344 5,079
Commitments and contingencies
Stockholders’ equity    
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of March 31, 2026 and June 30, 2025; and 120,920,243 and 122,694,263 shares outstanding as of March 31, 2026 and June 30, 2025, respectively 131 131
Additional paid-in capital 1,315 1,319
Retained earnings 223 432
Treasury stock, at cost: 9,821,218 and 8,047,198 shares as of March 31, 2026 and June 30, 2025, respectively (1,584) (1,404)
Accumulated other comprehensive net (loss) income (152) (157)
Total Clorox stockholders’ (deficit) equity (67) 321
Noncontrolling interests 159 161
Total stockholders’ equity 92 482
Total liabilities and stockholders’ equity $ 6,436 $ 5,561
v3.26.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2026
Jun. 30, 2025
Statement of Financial Position [Abstract]    
Property, plant and equipment, accumulated depreciation and amortization $ 3,044 $ 2,911
Preferred stock, par value (in dollars per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 130,741,461 130,741,461
Common stock, shares outstanding (in shares) 120,920,243 122,694,263
Treasury stock (in shares) 9,821,218 8,047,198
v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating activities:    
Net earnings $ 434 $ 488
Adjustments to reconcile net earnings to net cash provided by operations:    
Depreciation and amortization 169 162
Stock-based compensation 49 64
Deferred income taxes 135 (16)
Venture Agreement termination payment (476) 0
Loss on divestiture 0 112
Other (18) (9)
Changes in:    
Receivables, net 158 71
Inventories, net (64) (54)
Prepaid expenses and other current assets (14) (28)
Accounts payable and accrued liabilities (12) (87)
Operating lease right-of-use assets and liabilities, net (5) 1
Income taxes payable / prepaid (74) (17)
Net cash provided by operations 282 687
Investing activities:    
Capital expenditures (121) (145)
Proceeds from divestiture, net of cash divested 0 128
Other 1 (1)
Net cash used for investing activities (120) (18)
Financing activities:    
Notes and loans payable, net 1,581 50
Treasury stock purchased (256) (257)
Cash dividends paid to Clorox stockholders (452) (452)
Cash dividends paid to noncontrolling interests 0 (16)
Issuance of common stock for employee stock plans and other (16) 30
Net cash provided by (used for) financing activities 857 (645)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (2) (2)
Net increase (decrease) in cash, cash equivalents and restricted cash 1,017 22
Cash, cash equivalents and restricted cash:    
Beginning of period 170 207
End of period $ 1,187 $ 229
v3.26.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Statement of Comprehensive Income [Abstract]        
Net earnings $ 191 $ 191 $ 434 $ 488
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustments (4) 7 3 (13)
Net unrealized gains (losses) on derivatives 11 (2) 3 (7)
Pension and postretirement benefit adjustments 0 0 (1) (1)
Total other comprehensive (loss) income, net of tax 7 5 5 (21)
Comprehensive income 198 196 439 467
Less: Total comprehensive income attributable to noncontrolling interests 4 5 10 10
Total comprehensive income attributable to Clorox $ 194 $ 191 $ 429 $ 457
v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2026 and 2025, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Percentage and basis point calculations are based on rounded numbers, except for per share data and the effective tax rate.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2025, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In September 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06)”, which modernizes the accounting for internal-use software to current development practices, clarifies when to begin capitalizing costs and enhances disclosure requirements. The ASU is effective for annual reporting periods beginning after December 15, 2027, and for interim periods within those annual reporting periods, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” These amendments primarily require enhanced quantitative and qualitative disclosures in the notes to the financial statements for specific expense categories underlying the expenses presented on the income statement. These amendments are to be applied prospectively to financial statements issued after the effective date or retrospectively to any or all periods presented in the financial statements. Early adoption is permitted. The standard will be effective for annual periods beginning after December 15, 2026, and subsequent interim periods. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss on an annual and interim basis. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for the annual period beginning July 1, 2024 and interim periods beginning July 1, 2025. The Company adopted the annual requirement for fiscal year 2025 and interim requirements in the first quarter of fiscal year 2026.
v3.26.1
VENTURE AGREEMENT
 9 Months Ended
Mar. 31, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
VENTURE AGREEMENT VENTURE AGREEMENT
The Company’s venture agreement with The Procter & Gamble Company (P&G) for the Company’s Glad bags and wraps business (the Venture Agreement) expired on January 31, 2026. In connection with this agreement, P&G provided research and development (R&D) support to the Glad business. As of June 30, 2025, P&G had a 20% interest in the venture. The Company paid a royalty to P&G for its interest in the profits, losses and cash flows, as contractually defined, of the Glad business, which is included in Cost of products sold.
The Venture Agreement, at its expiration, required the Company to purchase P&G’s 20% interest for cash at fair value as established by predetermined valuation procedures. As of June 30, 2025, the estimated fair value of P&G’s interest in the venture was $476, of which $501 was recognized and reflected in Accounts payable and accrued liabilities in the Company’s condensed consolidated balance sheet.
On January 31, 2026, the Company and P&G agreed that the Company would purchase P&G’s 20% interest, which was paid in cash for $476 on March 2, 2026 and is reflected in Operating activities within the condensed consolidated statement of cash flows.
The Glad business will continue to retain the exclusive core intellectual property licenses contributed by P&G on a royalty-free basis for the licensed products marketed.
v3.26.1
DIVESTITURE
 9 Months Ended
Mar. 31, 2026
Discontinued Operations and Disposal Groups [Abstract]  
DIVESTITURE DIVESTITURE
Divestiture of Better Health Vitamins, Minerals and Supplements (VMS) Business
On September 10, 2024, the Company completed the divestiture of its Better Health VMS business. As a result of the transaction, the Company recorded an after tax loss of $118 during the first quarter of fiscal year 2025. Net sales of the Better Health VMS business for the three and nine months ended March 31, 2025 were $0 and $38, respectively. Refer to notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2025 for further information related to the Better Health VMS business divestiture.
v3.26.1
INVENTORIES, NET
 9 Months Ended
Mar. 31, 2026
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
Inventories, net consisted of the following as of:
3/31/20266/30/2025
Finished goods$489 $447 
Raw materials and packaging151 141 
Work in process23 15 
LIFO allowances(75)(80)
Total inventories, net$588 $523 
v3.26.1
SUPPLY CHAIN FINANCING PROGRAM
 9 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
SUPPLY CHAIN FINANCING PROGRAM SUPPLY CHAIN FINANCING PROGRAM
The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The Company’s operating cash flows are directly impacted as a result of the extension of payment terms with suppliers. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets or liquidity. The Company has not pledged any assets as security or provided guarantees under the SCF program.
All outstanding amounts related to suppliers participating in the SCF program are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets and the associated payments are included in operating activities within the condensed consolidated statements of cash flows. As of March 31, 2026 and June 30, 2025, the amount due to suppliers participating in the SCF program and included in Accounts payable and accrued liabilities was $185 and $236, respectively.
v3.26.1
DEBT
 9 Months Ended
Mar. 31, 2026
Debt Disclosure [Abstract]  
DEBT DEBT
Short-term borrowings
As of March 31, 2026, the Company had outstanding $1,591 of Notes and loans payable primarily comprised of U.S. commercial paper borrowings to finance the previously announced GOJO Industries, Inc. (GOJO) acquisition and fund the Venture Agreement termination payment. See Note 14 and Note 2 for additional details related to the acquisition and Venture Agreement payment, respectively.
The weighted average effective interest rate of notes and loans payable as of March 31, 2026 and June 30, 2025 was 4.00% and 4.61%, respectively.
Credit arrangements
On March 6, 2026, in connection with the acquisition of GOJO, the Company entered into a $1,000 364-day revolving credit agreement (the 364-Day Revolving Credit Agreement) that matures on March 5, 2027, and a $1,250 Delayed Draw Term Credit Agreement (the Delayed Draw Term Credit Agreement). Any loans under the Delayed Draw Term Credit Agreement mature on March 5, 2027. Amounts available under the 364-Day Revolving Credit Agreement are for general corporate purposes. The Delayed Draw Term Credit Agreement provides the Company with the ability to borrow up to $1,250 at the closing of the GOJO acquisition, subject to satisfaction of customary closing conditions for similar facilities, for the purpose of financing a portion of the consideration under the membership interest purchase agreement (the Acquisition Agreement), paying related fees and expenses and repaying certain indebtedness of GOJO as contemplated by the Acquisition Agreement, with remaining amounts available to Clorox for general corporate purposes. The 364-Day Revolving Credit Agreement and Delayed Draw Term Credit Agreement are incremental to the existing $1,200 revolving credit agreement available to Clorox for general corporate purposes that matures in March 2030.
There were no borrowings under the 364-Day Revolving Credit Agreement nor the Delayed Draw Term Credit Agreement as of March 31, 2026 and no borrowings under the $1,200 revolving credit agreement that matures in March 2030 as of March 31, 2026 or June 30, 2025. The 364-Day Revolving Credit Agreement and Delayed Draw Term Credit Agreement include certain restrictive covenants and limitations consistent with the existing revolving credit agreement, with which the Company was in compliance as of March 31, 2026.
v3.26.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
 9 Months Ended
Mar. 31, 2026
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments
The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.
Commodity Price Risk Management
The Company may use commodity futures, options and swap contracts to limit the impact of price volatility on a portion of its forecasted raw material requirements. These commodity derivatives may be exchange traded or over-the-counter contracts and generally have original contractual maturities of less than 2 years. Commodity purchase and options contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.
The notional amounts of outstanding commodity derivatives, which related primarily to exposures in soybean oil used for the food business and jet fuel used for the grilling business, were $29 and $36 as of March 31, 2026 and June 30, 2025, respectively.
Foreign Currency Risk Management
The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have original contractual maturities of less than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.
The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $41 and $67 as of March 31, 2026 and June 30, 2025, respectively.
Interest Rate Risk Management
The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have original contractual maturities of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.
The notional amounts of outstanding interest rate contracts used by the Company to hedge forecasted debt issuance were $200 and $0 as of March 31, 2026 and June 30, 2025, respectively. These contracts represent interest rate swap lock agreements to manage the exposure to interest rate volatility associated with future interest payments on the forecasted debt issuance as part of the GOJO acquisition.
Commodity, Foreign Exchange and Interest Rate Derivatives
The Company designates its commodity forward, futures and options contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Commodity purchase derivative contracts$14 $1 $13 $(2)
Foreign exchange derivative contracts— (1)— 1 
Interest rate derivative contracts5 — 5 — 
Total$19 $— $18 $(1)

Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Commodity purchase derivative contractsCost of products sold$— $(2)$2 $(5)
Foreign exchange derivative contractsCost of products sold(1)— (1)— 
Interest rate derivative contractsInterest expense4 4 10 10 
Total$3 $2 $11 $5 
The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2026 that is expected to be reclassified into Net earnings within the next twelve months is $26.
Counterparty Risk Management and Derivative Contract Requirements
The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions, $0 and $2 contained such terms as of March 31, 2026 and June 30, 2025, respectively. As of both March 31, 2026 and June 30, 2025, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.
Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the Company’s credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2026 and June 30, 2025, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.
Certain of the Company’s exchange traded futures and options contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of both March 31, 2026 and June 30, 2025, the Company maintained cash margin balances related to exchange traded futures and options contracts of $0 and $2, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.
Trust Assets
The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and therefore trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The gains and losses on the trust assets are recorded in Other (income) expense, net in the condensed consolidated statements of earnings and comprehensive income. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of both March 31, 2026 and June 30, 2025, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 3/31/20266/30/2025
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsPrepaid expenses and other current assets1$7 $7 $3 $3 
Commodity purchase swaps contractsPrepaid expenses and other current assets25 5 — — 
Commodity purchase futures contractsOther assets1— — 1 1 
Foreign exchange forward contractsPrepaid expenses and other current assets21 1 — — 
Interest rate forward contractsPrepaid expenses and other current assets25 5 — — 
 $18 $18 $4 $4 
Liabilities
Commodity purchase swaps contractsAccounts payable and accrued liabilities2$— $— $1 $1 
Foreign exchange forward contractsAccounts payable and accrued liabilities21 1 1 1 
$1 $1 $2 $2 
The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 3/31/20266/30/2025
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
 equivalents (1)
1$715 $715 $54 $54 
Time deposits
Cash and cash
equivalents (1)
2332 332 10 10 
Trust assets for nonqualified deferred compensation plansOther assets1171 171 169 169 
 $1,218 $1,218 $233 $233 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$1,591 $1,591 $4 $4 
Long-term debt
Long-term debt (3)
22,487 2,432 2,484 2,431 
$4,078 $4,023 $2,488 $2,435 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
v3.26.1
INCOME TAXES
 9 Months Ended
Mar. 31, 2026
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 25.4% and 24.9% for the three and nine months ended March 31, 2026, respectively, and 24.8% and 26.9% for the three and nine months ended March 31, 2025, respectively. The higher tax rate in the prior nine month period as compared to the current period was primarily driven by the nondeductibility of the loss on the divestiture of the Better Health VMS business, partially offset by an international legal entity reorganization and favorable stock-based compensation deductions, all in the prior period.
The One Big Beautiful Bill Act (OBBBA) was enacted in the United States on July 4, 2025. This legislation includes provisions that allow accelerated tax deductions for acquisitions of qualified property and for research expenses. It also modifies the U.S. taxation of certain earnings associated with international business. The Company assessed the provisions of the OBBBA and determined the corporate tax changes did not have a material impact on the effective tax rate in future periods. The OBBBA’s provisions for accelerated tax deductions will change the timing of cash tax payments in the current fiscal year and future periods.
v3.26.1
NET EARNINGS PER SHARE (EPS)
 9 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
NET EARNINGS PER SHARE (EPS) NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Basic121,363123,367121,865123,643
Dilutive effect of stock options and other424699375825
Diluted121,787124,066122,240124,468
Antidilutive stock options and other2,6671,575 2,667 1,575 
Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.
v3.26.1
OTHER (INCOME) EXPENSE, NET
 9 Months Ended
Mar. 31, 2026
Other Income and Expenses [Abstract]  
OTHER (INCOME) EXPENSE, NET OTHER (INCOME) EXPENSE, NET
The major components of Other (income) expense, net were:
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Amortization of trademarks and other intangible assets$5 $5 $15 $16 
Trust investment (gains) losses, net
3 2 (9)(6)
Net periodic benefit (credit) cost
1 3 2 — 
Foreign exchange transaction losses, net
2 (1)3 2 
Income from equity investees— — (2)(3)
Interest income(4)(2)(7)(7)
Cyberattack insurance recoveries (1)
— (33)— (65)
Other(1)(8)— (16)
Total$6 $(34)$2 $(79)
(1)On August 14, 2023, the Company experienced a cyberattack which resulted in wide-scale disruptions to the Company’s business operations. In the three and nine months ended March 31, 2025, the Company recorded insurance recoveries of $(35) and $(70) respectively, of which $(2) and $(5) respectively was recorded in Cost of products sold and the remainder was recorded in Other (income) expense, net. Business interruption and other insurance recoveries that do not correspond directly to previously incurred expenses are recognized in Other (income) expense, net. Refer to notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2025 for further information related to the August 2023 Cyberattack.
v3.26.1
STOCKHOLDERS' EQUITY
 9 Months Ended
Mar. 31, 2026
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three months ended March 31
(Dollars in millions except per share data; shares in thousands)
Common stockAdditional paid-in capitalRetained earningsTreasury stockAccumulated
other
comprehensive
net (loss) income		Noncontrolling interestsTotal stockholders’ equity
AmountShares AmountShares
Balance as of December 31, 2024$131 130,741 $1,287 $68 $(1,346)(7,591)$(181)$162 $121 
Net earnings— — — 186 — — — 5 191 
Other comprehensive (loss) income— — — — — — 5 — 5 
Dividends to Clorox stockholders ($1.22 per share declared)
— — — (152)— — — — (152)
Dividends to noncontrolling interests— — — — — — — (4)(4)
Stock-based compensation— — 24 — — — — — 24 
Other employee stock plan activities— — (7)(3)15 101 — — 5 
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Balance as of December 31, 2025$131 130,741 $1,304 $190 $(1,591)(9,851)$(159)$160 $35 
Net earnings— — — 187 — — — 4 191 
Other comprehensive (loss) income— — — — — — 7 — 7 
Dividends to Clorox stockholders ($1.24 per share declared)
— — — (152)— — — — (152)
Dividends to noncontrolling interests— — — — — — — (5)(5)
Stock-based compensation— — 15 — — — — — 15 
Other employee stock plan activities— — (4)(2)7 30 — — 1 
Balance as of March 31, 2026$131 130,741 $1,315 $223 $(1,584)(9,821)$(152)$159 $92 
Nine months ended March 31
(Dollars in millions except per share data; shares in thousands)Common stockAdditional paid-in capital
Retained earnings
Treasury stock
Accumulated
other
comprehensive
net (loss) income
Noncontrolling interests
Total stockholders’ equity
AmountSharesAmountShares
Balance as of June 30, 2024$131 130,741 $1,288 $250 $(1,186)(6,540)$(155)$164 $492 
Net earnings— — — 478 — — — 10 488 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($4.88 per share declared)
— — — (609)— — — — (609)
Dividends to noncontrolling interests— — — — — — — (11)(11)
Stock-based compensation— — 64 — — — — — 64 
Other employee stock plan activities— — (48)(20)112 745 — — 44 
Treasury stock purchased— — — — (257)(1,695)— — (257)
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Balance as of June 30, 2025$131 130,741 $1,319 $432 $(1,404)(8,047)$(157)$161 $482 
Net earnings— — — 424 — — — 10 434 
Other comprehensive (loss) income— — — — — — 5 — 5 
Dividends to Clorox stockholders ($4.96 per share declared)
— — — (608)— — — — (608)
Dividends to noncontrolling interests— — — — — — — (12)(12)
Stock-based compensation— — 49 — — — — — 49 
Other employee stock plan activities— — (53)(25)78 383 — — — 
Treasury stock purchased— — — — (258)(2,157)— — (258)
Balance as of March 31, 2026$131 130,741 $1,315 $223 $(1,584)(9,821)$(152)$159 $92 
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of December 31, 2024$(259)$80 $(2)$(181)
Other comprehensive (loss) income before reclassifications6 — — 6 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (2)— (2)
Income tax benefit (expense)1 — — 1 
Net current period other comprehensive (loss) income7 (2)— 5 
Balance as of March 31, 2025$(252)$78 $(2)$(176)
Balance as of December 31, 2025$(226)$69 $(2)$(159)
Other comprehensive (loss) income before reclassifications(4)19 — 15 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (3)— (3)
Income tax benefit (expense)
— (5)— (5)
Net current period other comprehensive (loss) income(4)11 — 7 
Balance as of March 31, 2026$(230)$80 $(2)$(152)
Nine months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivatives
Pension and postretirement benefit adjustments
Accumulated other comprehensive net (loss) income
Balance as of June 30, 2024$(239)$85 $(1)$(155)
Other comprehensive (loss) income before reclassifications(14)(1)— (15)
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (5)(1)(6)
Income tax benefit (expense)1 (1)— — 
Net current period other comprehensive (loss) income(13)(7)(1)(21)
Balance as of March 31, 2025$(252)$78 $(2)$(176)
Balance as of June 30, 2025
$(233)$77 $(1)$(157)
Other comprehensive (loss) income before reclassifications2 18 — 20 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (11)(1)(12)
Income tax benefit (expense)
1 (4)— (3)
Net current period other comprehensive (loss) income3 3 (1)5 
Balance as of March 31, 2026$(230)$80 $(2)$(152)
v3.26.1
OTHER CONTINGENCIES AND GUARANTEES
 9 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company recorded liabilities totaling $28 and $27 as of March 31, 2026 and June 30, 2025, respectively, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $12 of the recorded liability as of both March 31, 2026 and June 30, 2025, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, groundwater, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs (including any related to soil, groundwater, soil vapor and indoor air impacts) are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both March 31, 2026 and June 30, 2025. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time.
The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. From time to time, the Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company has provided certain indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of both March 31, 2026 and June 30, 2025.
The Company was a party to letters of credit of $18 as of March 31, 2026, primarily related to its insurance carriers, of which $0 had been drawn upon.
v3.26.1
SEGMENT RESULTS
 9 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT RESULTS SEGMENT RESULTS
The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other.
Corporate and Other includes certain non-allocated administrative and other costs and various other non-operating income and expenses, as well as the results of the Better Health VMS business through the date of divestiture. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The principal measure of segment profitability used by the Chief Operating Decision Maker (CODM), identified as the Company's Chair and Chief Executive Officer, is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental charges and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the digital capabilities and productivity enhancements investment, transaction and integration costs related to acquisitions, significant losses related to divestitures and other nonrecurring or unusual items impacting comparability).
The CODM uses this measure to assess the operating results and performance of its segments, monitor actual results as compared to plan, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment’s underlying operations.
Net sales by segment and a reconciliation to the Company’s consolidated net sales for the three and nine months ended March 31:
Net sales
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Health and Wellness$629 $630 $1,837 $1,956 
Household482 469 1,263 1,362 
Lifestyle277 306 843 964 
International285 263 832 796 
Reportable segment total
$1,673 $1,668 $4,775 $5,078 
Corporate and Other(3)— (3)38 
Total$1,670 $1,668 $4,772 $5,116 
All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Segment adjusted EBIT, including the significant segment expense provided to the CODM, and a reconciliation to earnings before income taxes for the three and nine months ended March 31:
Segment adjusted earnings (losses) before interest and income taxes
Three months ended March 31, 2026
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$629 $482 $277 $285 
Cost of products sold
319 316 146 177 
Other segment items (1)
152 92 71 72 
Segment adjusted EBIT
$158 $74 $60 $36 $328 
Corporate and Other
(32)
Interest income4 
Interest expense(27)
Acquisition and integration costs (2)
(7)
Digital capabilities and productivity enhancements investment (3)
(10)
Earnings before income taxes
$256 
Segment adjusted earnings (losses) before interest and income taxes
Nine months ended March 31, 2026
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$1,837 $1,263 $843 $832 
Cost of products sold
919 858 430 530 
Other segment items (1)
446 282 243 216 
Segment adjusted EBIT
$472 $123 $170 $86 $851 
Corporate and Other
(139)
Interest income7 
Interest expense(75)
Acquisition and integration costs (2)
(7)
Digital capabilities and productivity enhancements investment (3)
(59)
Earnings before income taxes
$578 
(1)Other segment items includes selling and administrative expenses, advertising costs, research and development costs and other income and expenses. The items defined in segment adjusted EBIT above are excluded from other segment items and Corporate and Other.
(2)Represents the expenses related to the Company’s acquisition and integration of GOJO corresponding to Corporate and Other. See Note 14 for additional details related to the acquisition.
(3)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Segment adjusted earnings (losses) before interest and income taxes
Three months ended March 31, 2025
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$630 $469 $306 $263 
Cost of products sold
305 308 154 162 
Other segment items (1)
156 100 92 70 
Segment adjusted EBIT
$169 $61 $60 $31 $321 
Corporate and Other
(55)
Interest income2 
Interest expense(23)
Loss on divestiture (2)
— 
Cyberattack costs, net of insurance recoveries (3)
35 
Digital capabilities and productivity enhancements investment (4)
(26)
Earnings before income taxes
$254 
Segment adjusted earnings (losses) before interest and income taxes
Nine months ended March 31, 2025
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$1,956 $1,362 $964 $796 
Cost of products sold
928 897 479 495 
Other segment items (1)
431 296 289 214 
Segment adjusted EBIT
$597 $169 $196 $87 $1,049 
Corporate and Other
(193)
Interest income7 
Interest expense(66)
Loss on divestiture (2)
(118)
Cyberattack costs, net of insurance recoveries (3)
70 
Digital capabilities and productivity enhancements investment (4)
(81)
Earnings before income taxes
$668 
(1)Other segment items includes selling and administrative expenses, advertising costs, research and development costs and other income and expenses. The items defined in segment adjusted EBIT above are excluded from other segment items and Corporate and Other.
(2)Represents the loss on divestiture of the Better Health VMS business corresponding to Corporate and Other. See Note 3 for additional details related to the divestiture.
(3)Represents insurance recoveries related to the cyberattack corresponding to Corporate and Other. See Note 10 for further discussion.
(4)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Certain other segment disclosures were as follows:
Health and WellnessHouseholdLifestyleInternational
Corporate and Other
Total
Company
Total assets
Balance as of 3/31/2026
$1,198 $1,085 $1,098 $1,306 $1,749 $6,436 
Balance as of 6/30/2025
1,217 1,091 1,103 1,329 821 5,561 
(Income) Loss from equity investees included in Other (income) expense, net
Three months ended 03/31/2026— — — — — — 
Three months ended 03/31/2025— — — — — — 
Nine months ended 03/31/2026— — — (2)— (2)
Nine months ended 03/31/2025— — — (3)— (3)
Capital expenditures
Three months ended 03/31/202613 15 6 9 — 43 
Three months ended 03/31/202515 19 9 7 3 53 
Nine months ended 03/31/202636 47 18 17 3 121 
Nine months ended 03/31/202538 58 28 13 8 145 
Depreciation and amortization
Three months ended 3/31/2026
15 22 6 11 4 58 
Three months ended 3/31/2025
14 20 7 10 4 55 
Nine months ended 03/31/202644 63 20 32 10 169 
Nine months ended 03/31/202542 58 18 31 13 162 
Significant noncash charges included in earnings before interest and income taxes:
Stock-based compensation
Three months ended 3/31/2026
4 2 2 1 6 15 
Three months ended 3/31/2025
4 3 2 2 13 24 
Nine months ended 03/31/202612 8 6 4 19 49 
Nine months ended 03/31/202512 9 6 5 32 64 
Net sales to the Company’s largest customer, Walmart Inc. and its affiliates, as a percentage of consolidated net sales, was 28% and 27% for the three and nine months ended March 31, 2026, respectively, and 27% and 26% for the three and nine months ended March 31, 2025, respectively.
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:
Net sales
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Cleaning33 %33 %33 %33 %
Professional Products5 5 5 5 
Health and Wellness38 %38 %38 %38 %
Bags and Wraps12 12 12 12 
Cat Litter8 8 9 9 
Grilling9 8 6 6 
Household29 %28 %27 %27 %
Food11 11 10 11 
Water Filtration2 4 4 4 
Natural Personal Care3 3 4 4 
Lifestyle16 %18 %18 %19 %
International17 %16 %17 %15 %
Corporate and Other— %— %— %1 %
Total Company100 %100 %100 %100 %
v3.26.1
SUBSEQUENT EVENTS
 9 Months Ended
Mar. 31, 2026
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
On April 1, 2026, the Company completed the previously announced acquisition of GOJO, makers of Purell and a leader of skin health and hygiene solutions. The Company acquired all of the issued and outstanding membership interests of GOJO, which is based in northeast Ohio. The acquisition reflects the Company's strategy to expand its position in health and hygiene and accelerate profitable growth.
The acquisition was completed for a purchase price of approximately $2,250, but may ultimately be adjusted for indebtedness assumed, cash acquired and working capital and other adjustments. To finance the acquisition, the Company drew down $1,250 from the Delayed Draw Term Credit Agreement and used cash from commercial paper borrowings issued prior to March 31, 2026; see Note 6 for further details.
The GOJO acquisition will be accounted for as a business combination under the acquisition method of accounting with the purchase price allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their fair values at the acquisition date. Due to the limited time since the closing of the transaction, the Company is in the process of completing its initial fair value estimates, which will be disclosed in the fourth quarter of fiscal year 2026. The Company expects the majority of the purchase price to be allocated to Goodwill, Trademarks, net and Other intangible assets, net.
v3.26.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2026 and 2025, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Percentage and basis point calculations are based on rounded numbers, except for per share data and the effective tax rate.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2025, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In September 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06)”, which modernizes the accounting for internal-use software to current development practices, clarifies when to begin capitalizing costs and enhances disclosure requirements. The ASU is effective for annual reporting periods beginning after December 15, 2027, and for interim periods within those annual reporting periods, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” These amendments primarily require enhanced quantitative and qualitative disclosures in the notes to the financial statements for specific expense categories underlying the expenses presented on the income statement. These amendments are to be applied prospectively to financial statements issued after the effective date or retrospectively to any or all periods presented in the financial statements. Early adoption is permitted. The standard will be effective for annual periods beginning after December 15, 2026, and subsequent interim periods. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss on an annual and interim basis. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for the annual period beginning July 1, 2024 and interim periods beginning July 1, 2025. The Company adopted the annual requirement for fiscal year 2025 and interim requirements in the first quarter of fiscal year 2026.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of both March 31, 2026 and June 30, 2025, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Results
The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other.
Corporate and Other includes certain non-allocated administrative and other costs and various other non-operating income and expenses, as well as the results of the Better Health VMS business through the date of divestiture. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The principal measure of segment profitability used by the Chief Operating Decision Maker (CODM), identified as the Company's Chair and Chief Executive Officer, is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental charges and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the digital capabilities and productivity enhancements investment, transaction and integration costs related to acquisitions, significant losses related to divestitures and other nonrecurring or unusual items impacting comparability).
The CODM uses this measure to assess the operating results and performance of its segments, monitor actual results as compared to plan, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment’s underlying operations.
v3.26.1
INVENTORIES, NET (Tables)
 9 Months Ended
Mar. 31, 2026
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories, net consisted of the following as of:
3/31/20266/30/2025
Finished goods$489 $447 
Raw materials and packaging151 141 
Work in process23 15 
LIFO allowances(75)(80)
Total inventories, net$588 $523 
v3.26.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Mar. 31, 2026
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Commodity purchase derivative contracts$14 $1 $13 $(2)
Foreign exchange derivative contracts— (1)— 1 
Interest rate derivative contracts5 — 5 — 
Total$19 $— $18 $(1)
Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings
Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Commodity purchase derivative contractsCost of products sold$— $(2)$2 $(5)
Foreign exchange derivative contractsCost of products sold(1)— (1)— 
Interest rate derivative contractsInterest expense4 4 10 10 
Total$3 $2 $11 $5 
Schedule of Assets and Liabilities for Fair Value of Derivative Instruments and Fair Value Disclosure The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 3/31/20266/30/2025
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsPrepaid expenses and other current assets1$7 $7 $3 $3 
Commodity purchase swaps contractsPrepaid expenses and other current assets25 5 — — 
Commodity purchase futures contractsOther assets1— — 1 1 
Foreign exchange forward contractsPrepaid expenses and other current assets21 1 — — 
Interest rate forward contractsPrepaid expenses and other current assets25 5 — — 
 $18 $18 $4 $4 
Liabilities
Commodity purchase swaps contractsAccounts payable and accrued liabilities2$— $— $1 $1 
Foreign exchange forward contractsAccounts payable and accrued liabilities21 1 1 1 
$1 $1 $2 $2 
The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 3/31/20266/30/2025
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
 equivalents (1)
1$715 $715 $54 $54 
Time deposits
Cash and cash
equivalents (1)
2332 332 10 10 
Trust assets for nonqualified deferred compensation plansOther assets1171 171 169 169 
 $1,218 $1,218 $233 $233 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$1,591 $1,591 $4 $4 
Long-term debt
Long-term debt (3)
22,487 2,432 2,484 2,431 
$4,078 $4,023 $2,488 $2,435 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
v3.26.1
NET EARNINGS PER SHARE (EPS) (Tables)
 9 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares Outstanding
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Basic121,363123,367121,865123,643
Dilutive effect of stock options and other424699375825
Diluted121,787124,066122,240124,468
Antidilutive stock options and other2,6671,575 2,667 1,575 
v3.26.1
OTHER (INCOME) EXPENSE, NET (Tables)
 9 Months Ended
Mar. 31, 2026
Other Income and Expenses [Abstract]  
Schedule of Major Components of Other (Income) Expense, Net
The major components of Other (income) expense, net were:
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Amortization of trademarks and other intangible assets$5 $5 $15 $16 
Trust investment (gains) losses, net
3 2 (9)(6)
Net periodic benefit (credit) cost
1 3 2 — 
Foreign exchange transaction losses, net
2 (1)3 2 
Income from equity investees— — (2)(3)
Interest income(4)(2)(7)(7)
Cyberattack insurance recoveries (1)
— (33)— (65)
Other(1)(8)— (16)
Total$6 $(34)$2 $(79)
(1)On August 14, 2023, the Company experienced a cyberattack which resulted in wide-scale disruptions to the Company’s business operations. In the three and nine months ended March 31, 2025, the Company recorded insurance recoveries of $(35) and $(70) respectively, of which $(2) and $(5) respectively was recorded in Cost of products sold and the remainder was recorded in Other (income) expense, net. Business interruption and other insurance recoveries that do not correspond directly to previously incurred expenses are recognized in Other (income) expense, net. Refer to notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2025 for further information related to the August 2023 Cyberattack.
v3.26.1
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Mar. 31, 2026
Equity [Abstract]  
Schedule of Changes in Components of Stockholders’ Equity
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three months ended March 31
(Dollars in millions except per share data; shares in thousands)
Common stockAdditional paid-in capitalRetained earningsTreasury stockAccumulated
other
comprehensive
net (loss) income		Noncontrolling interestsTotal stockholders’ equity
AmountShares AmountShares
Balance as of December 31, 2024$131 130,741 $1,287 $68 $(1,346)(7,591)$(181)$162 $121 
Net earnings— — — 186 — — — 5 191 
Other comprehensive (loss) income— — — — — — 5 — 5 
Dividends to Clorox stockholders ($1.22 per share declared)
— — — (152)— — — — (152)
Dividends to noncontrolling interests— — — — — — — (4)(4)
Stock-based compensation— — 24 — — — — — 24 
Other employee stock plan activities— — (7)(3)15 101 — — 5 
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Balance as of December 31, 2025$131 130,741 $1,304 $190 $(1,591)(9,851)$(159)$160 $35 
Net earnings— — — 187 — — — 4 191 
Other comprehensive (loss) income— — — — — — 7 — 7 
Dividends to Clorox stockholders ($1.24 per share declared)
— — — (152)— — — — (152)
Dividends to noncontrolling interests— — — — — — — (5)(5)
Stock-based compensation— — 15 — — — — — 15 
Other employee stock plan activities— — (4)(2)7 30 — — 1 
Balance as of March 31, 2026$131 130,741 $1,315 $223 $(1,584)(9,821)$(152)$159 $92 
Nine months ended March 31
(Dollars in millions except per share data; shares in thousands)Common stockAdditional paid-in capital
Retained earnings
Treasury stock
Accumulated
other
comprehensive
net (loss) income
Noncontrolling interests
Total stockholders’ equity
AmountSharesAmountShares
Balance as of June 30, 2024$131 130,741 $1,288 $250 $(1,186)(6,540)$(155)$164 $492 
Net earnings— — — 478 — — — 10 488 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($4.88 per share declared)
— — — (609)— — — — (609)
Dividends to noncontrolling interests— — — — — — — (11)(11)
Stock-based compensation— — 64 — — — — — 64 
Other employee stock plan activities— — (48)(20)112 745 — — 44 
Treasury stock purchased— — — — (257)(1,695)— — (257)
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Balance as of June 30, 2025$131 130,741 $1,319 $432 $(1,404)(8,047)$(157)$161 $482 
Net earnings— — — 424 — — — 10 434 
Other comprehensive (loss) income— — — — — — 5 — 5 
Dividends to Clorox stockholders ($4.96 per share declared)
— — — (608)— — — — (608)
Dividends to noncontrolling interests— — — — — — — (12)(12)
Stock-based compensation— — 49 — — — — — 49 
Other employee stock plan activities— — (53)(25)78 383 — — — 
Treasury stock purchased— — — — (258)(2,157)— — (258)
Balance as of March 31, 2026$131 130,741 $1,315 $223 $(1,584)(9,821)$(152)$159 $92 
Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of December 31, 2024$(259)$80 $(2)$(181)
Other comprehensive (loss) income before reclassifications6 — — 6 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (2)— (2)
Income tax benefit (expense)1 — — 1 
Net current period other comprehensive (loss) income7 (2)— 5 
Balance as of March 31, 2025$(252)$78 $(2)$(176)
Balance as of December 31, 2025$(226)$69 $(2)$(159)
Other comprehensive (loss) income before reclassifications(4)19 — 15 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (3)— (3)
Income tax benefit (expense)
— (5)— (5)
Net current period other comprehensive (loss) income(4)11 — 7 
Balance as of March 31, 2026$(230)$80 $(2)$(152)
Nine months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivatives
Pension and postretirement benefit adjustments
Accumulated other comprehensive net (loss) income
Balance as of June 30, 2024$(239)$85 $(1)$(155)
Other comprehensive (loss) income before reclassifications(14)(1)— (15)
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (5)(1)(6)
Income tax benefit (expense)1 (1)— — 
Net current period other comprehensive (loss) income(13)(7)(1)(21)
Balance as of March 31, 2025$(252)$78 $(2)$(176)
Balance as of June 30, 2025
$(233)$77 $(1)$(157)
Other comprehensive (loss) income before reclassifications2 18 — 20 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (11)(1)(12)
Income tax benefit (expense)
1 (4)— (3)
Net current period other comprehensive (loss) income3 3 (1)5 
Balance as of March 31, 2026$(230)$80 $(2)$(152)
v3.26.1
SEGMENT RESULTS (Tables)
 9 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information and Reconciliation of Segment Information
Net sales by segment and a reconciliation to the Company’s consolidated net sales for the three and nine months ended March 31:
Net sales
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Health and Wellness$629 $630 $1,837 $1,956 
Household482 469 1,263 1,362 
Lifestyle277 306 843 964 
International285 263 832 796 
Reportable segment total
$1,673 $1,668 $4,775 $5,078 
Corporate and Other(3)— (3)38 
Total$1,670 $1,668 $4,772 $5,116 
Segment adjusted EBIT, including the significant segment expense provided to the CODM, and a reconciliation to earnings before income taxes for the three and nine months ended March 31:
Segment adjusted earnings (losses) before interest and income taxes
Three months ended March 31, 2026
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$629 $482 $277 $285 
Cost of products sold
319 316 146 177 
Other segment items (1)
152 92 71 72 
Segment adjusted EBIT
$158 $74 $60 $36 $328 
Corporate and Other
(32)
Interest income4 
Interest expense(27)
Acquisition and integration costs (2)
(7)
Digital capabilities and productivity enhancements investment (3)
(10)
Earnings before income taxes
$256 
Segment adjusted earnings (losses) before interest and income taxes
Nine months ended March 31, 2026
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$1,837 $1,263 $843 $832 
Cost of products sold
919 858 430 530 
Other segment items (1)
446 282 243 216 
Segment adjusted EBIT
$472 $123 $170 $86 $851 
Corporate and Other
(139)
Interest income7 
Interest expense(75)
Acquisition and integration costs (2)
(7)
Digital capabilities and productivity enhancements investment (3)
(59)
Earnings before income taxes
$578 
(1)Other segment items includes selling and administrative expenses, advertising costs, research and development costs and other income and expenses. The items defined in segment adjusted EBIT above are excluded from other segment items and Corporate and Other.
(2)Represents the expenses related to the Company’s acquisition and integration of GOJO corresponding to Corporate and Other. See Note 14 for additional details related to the acquisition.
(3)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Segment adjusted earnings (losses) before interest and income taxes
Three months ended March 31, 2025
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$630 $469 $306 $263 
Cost of products sold
305 308 154 162 
Other segment items (1)
156 100 92 70 
Segment adjusted EBIT
$169 $61 $60 $31 $321 
Corporate and Other
(55)
Interest income2 
Interest expense(23)
Loss on divestiture (2)
— 
Cyberattack costs, net of insurance recoveries (3)
35 
Digital capabilities and productivity enhancements investment (4)
(26)
Earnings before income taxes
$254 
Segment adjusted earnings (losses) before interest and income taxes
Nine months ended March 31, 2025
Health and Wellness
Household
Lifestyle
International
Total
Net sales
$1,956 $1,362 $964 $796 
Cost of products sold
928 897 479 495 
Other segment items (1)
431 296 289 214 
Segment adjusted EBIT
$597 $169 $196 $87 $1,049 
Corporate and Other
(193)
Interest income7 
Interest expense(66)
Loss on divestiture (2)
(118)
Cyberattack costs, net of insurance recoveries (3)
70 
Digital capabilities and productivity enhancements investment (4)
(81)
Earnings before income taxes
$668 
(1)Other segment items includes selling and administrative expenses, advertising costs, research and development costs and other income and expenses. The items defined in segment adjusted EBIT above are excluded from other segment items and Corporate and Other.
(2)Represents the loss on divestiture of the Better Health VMS business corresponding to Corporate and Other. See Note 3 for additional details related to the divestiture.
(3)Represents insurance recoveries related to the cyberattack corresponding to Corporate and Other. See Note 10 for further discussion.
(4)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Certain other segment disclosures were as follows:
Health and WellnessHouseholdLifestyleInternational
Corporate and Other
Total
Company
Total assets
Balance as of 3/31/2026
$1,198 $1,085 $1,098 $1,306 $1,749 $6,436 
Balance as of 6/30/2025
1,217 1,091 1,103 1,329 821 5,561 
(Income) Loss from equity investees included in Other (income) expense, net
Three months ended 03/31/2026— — — — — — 
Three months ended 03/31/2025— — — — — — 
Nine months ended 03/31/2026— — — (2)— (2)
Nine months ended 03/31/2025— — — (3)— (3)
Capital expenditures
Three months ended 03/31/202613 15 6 9 — 43 
Three months ended 03/31/202515 19 9 7 3 53 
Nine months ended 03/31/202636 47 18 17 3 121 
Nine months ended 03/31/202538 58 28 13 8 145 
Depreciation and amortization
Three months ended 3/31/2026
15 22 6 11 4 58 
Three months ended 3/31/2025
14 20 7 10 4 55 
Nine months ended 03/31/202644 63 20 32 10 169 
Nine months ended 03/31/202542 58 18 31 13 162 
Significant noncash charges included in earnings before interest and income taxes:
Stock-based compensation
Three months ended 3/31/2026
4 2 2 1 6 15 
Three months ended 3/31/2025
4 3 2 2 13 24 
Nine months ended 03/31/202612 8 6 4 19 49 
Nine months ended 03/31/202512 9 6 5 32 64 
Schedule of Concentration Percentage
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:
Net sales
Three months endedNine months ended
3/31/20263/31/20253/31/20263/31/2025
Cleaning33 %33 %33 %33 %
Professional Products5 5 5 5 
Health and Wellness38 %38 %38 %38 %
Bags and Wraps12 12 12 12 
Cat Litter8 8 9 9 
Grilling9 8 6 6 
Household29 %28 %27 %27 %
Food11 11 10 11 
Water Filtration2 4 4 4 
Natural Personal Care3 3 4 4 
Lifestyle16 %18 %18 %19 %
International17 %16 %17 %15 %
Corporate and Other— %— %— %1 %
Total Company100 %100 %100 %100 %
v3.26.1
VENTURE AGREEMENT (Details) - USD ($)
$ in Millions
 9 Months Ended
Mar. 02, 2026
Mar. 31, 2026
Mar. 31, 2025
Jan. 31, 2026
Jun. 30, 2025
Business Combination, Pro Forma Information [Line Items]          
Venture agreement, terminal obligation         $ 476
Venture agreement terminal obligation, net         $ 501
Venture Agreement termination payment   $ 476 $ 0    
Glad Business          
Business Combination, Pro Forma Information [Line Items]          
Venture Agreement termination payment $ 476        
Glad Business          
Business Combination, Pro Forma Information [Line Items]          
Percent ownership by venture partner       20.00% 20.00%
v3.26.1
DIVESTITURE (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Sep. 30, 2024
Mar. 31, 2026
Mar. 31, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Loss on divestiture $ 0 $ 0   $ 0 $ 118
Vitamins, Minerals and Supplements Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Loss on divestiture     $ 118    
Net sales   $ 0     $ 38
v3.26.1
INVENTORIES, NET (Details) - USD ($)
$ in Millions
Mar. 31, 2026
Jun. 30, 2025
Inventory Disclosure [Abstract]    
Finished goods $ 489 $ 447
Raw materials and packaging 151 141
Work in process 23 15
LIFO allowances (75) (80)
Total inventories, net $ 588 $ 523
v3.26.1
SUPPLY CHAIN FINANCING PROGRAM (Details) - USD ($)
$ in Millions
Mar. 31, 2026
Jun. 30, 2025
Supplier Finance Program [Line Items]    
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Amount due to suppliers participating in SCF $ 185 $ 236
Maximum    
Supplier Finance Program [Line Items]    
Supplier finance program, payment timing, period 120 days  
v3.26.1
DEBT (Details) - USD ($)
Mar. 31, 2026
Mar. 06, 2026
Jun. 30, 2025
Mar. 25, 2025
Debt Instrument [Line Items]        
Notes and loans payable $ 1,591,000,000   $ 4,000,000  
Weighted average effective interest rate, percent 4.00%   4.61%  
Revolving Credit Facility | 364-Day Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Line of credit facility, borrowing capacity   $ 1,000,000,000    
Line of credit facility, amount outstanding $ 0      
Revolving Credit Facility | 2025 Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Line of credit facility, borrowing capacity       $ 1,200,000,000
Line of credit facility, amount outstanding 0   $ 0  
Delayed Draw Term Loan (DDTL) | Delayed Draw Term Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Line of credit facility, borrowing capacity   $ 1,250,000,000    
Line of credit facility, amount outstanding $ 0      
v3.26.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2026
Jun. 30, 2025
Derivative [Line Items]    
Maximum contract duration (in years) 2 years  
Maximum duration, interest rate contracts (in years) 3 years  
Cash flow hedge gain (loss) to be reclassified within twelve months $ 26  
Derivative instruments subject to contractually defined counterparty liability position limits 0 $ 2
Interest rate forward contracts    
Derivative [Line Items]    
Derivative, notional amount 200 0
Commodity purchase derivative contracts    
Derivative [Line Items]    
Cash margin balances amount 0 2
Purchases of Inventory | Foreign exchange derivative contracts    
Derivative [Line Items]    
Derivative, notional amount $ 41 67
Total Commodity Purchase Derivative Contracts    
Derivative [Line Items]    
Maximum duration, commodity contracts (in years) 2 years  
Derivative, notional amount $ 29 $ 36
v3.26.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income $ 19 $ 0 $ 18 $ (1)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 3 2 11 5
Commodity purchase derivative contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 14 1 13 (2)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 0 (2) 2 (5)
Foreign exchange derivative contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 0 (1) 0 1
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (1) 0 (1) 0
Interest rate derivative contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 5 0 5 0
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings $ 4 $ 4 $ 10 $ 10
v3.26.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details) - USD ($)
$ in Millions
Mar. 31, 2026
Jun. 30, 2025
Assets    
Cash and cash equivalents $ 1,187 $ 167
Total assets 6,436 5,561
Liabilities    
Notes and loans payable, carrying value 1,591 4
Total liabilities 6,344 5,079
Carrying Amount    
Assets    
Derivative assets 18 4
Total assets 1,218 233
Liabilities    
Derivative liabilities 1 2
Total liabilities 4,078 2,488
Estimated Fair Value    
Assets    
Derivative assets 18 4
Total assets, estimated fair value 1,218 233
Liabilities    
Derivative liabilities 1 2
Total liabilities, estimated fair value 4,023 2,435
Fair Value, Inputs, Level 1 | Carrying Amount    
Assets    
Trust assets for nonqualified deferred compensation plans 171 169
Fair Value, Inputs, Level 1 | Estimated Fair Value    
Assets    
Trust assets for nonqualified deferred compensation plans, estimated fair value 171 169
Fair Value, Inputs, Level 2 | Carrying Amount | Long-term debt    
Liabilities    
Long-term debt 2,487 2,484
Fair Value, Inputs, Level 2 | Carrying Amount | Notes and loans payable    
Liabilities    
Notes and loans payable, carrying value 1,591 4
Fair Value, Inputs, Level 2 | Estimated Fair Value | Long-term debt    
Liabilities    
Long-term debt, estimated fair value 2,432 2,431
Fair Value, Inputs, Level 2 | Estimated Fair Value | Notes and loans payable    
Liabilities    
Notes and loans payable, estimated fair value 1,591 4
Interest-bearing investments, including money market funds | Fair Value, Inputs, Level 1 | Carrying Amount    
Assets    
Cash and cash equivalents 715 54
Interest-bearing investments, including money market funds | Fair Value, Inputs, Level 1 | Estimated Fair Value    
Assets    
Cash and cash equivalents, estimated fair value 715 54
Time deposits | Fair Value, Inputs, Level 2 | Carrying Amount    
Assets    
Cash and cash equivalents 332 10
Time deposits | Fair Value, Inputs, Level 2 | Estimated Fair Value    
Assets    
Cash and cash equivalents, estimated fair value 332 10
Commodity purchase futures contracts | Fair Value, Inputs, Level 1 | Carrying Amount | Prepaid expenses and other current assets    
Assets    
Derivative assets 7 3
Commodity purchase futures contracts | Fair Value, Inputs, Level 1 | Carrying Amount | Other assets    
Assets    
Derivative assets 0 1
Commodity purchase futures contracts | Fair Value, Inputs, Level 1 | Estimated Fair Value | Prepaid expenses and other current assets    
Assets    
Derivative assets 7 3
Commodity purchase futures contracts | Fair Value, Inputs, Level 1 | Estimated Fair Value | Other assets    
Assets    
Derivative assets 0 1
Commodity purchase futures contracts | Fair Value, Inputs, Level 2 | Carrying Amount    
Assets    
Derivative assets 5 0
Liabilities    
Derivative liabilities 0 1
Commodity purchase futures contracts | Fair Value, Inputs, Level 2 | Estimated Fair Value    
Assets    
Derivative assets 5 0
Liabilities    
Derivative liabilities 0 1
Foreign exchange forward contracts | Fair Value, Inputs, Level 2 | Carrying Amount    
Assets    
Derivative assets 1 0
Liabilities    
Derivative liabilities 1 1
Foreign exchange forward contracts | Fair Value, Inputs, Level 2 | Estimated Fair Value    
Assets    
Derivative assets 1 0
Liabilities    
Derivative liabilities 1 1
Interest rate forward contracts | Fair Value, Inputs, Level 2 | Carrying Amount    
Assets    
Derivative assets 5 0
Interest rate forward contracts | Fair Value, Inputs, Level 2 | Estimated Fair Value    
Assets    
Derivative assets $ 5 $ 0
v3.26.1
INCOME TAXES (Details)
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Income Tax Disclosure [Abstract]        
Effective tax rate on earnings 25.40% 24.80% 24.90% 26.90%
v3.26.1
NET EARNINGS PER SHARE (EPS) (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Earnings Per Share [Abstract]        
Basic (in shares) 121,363 123,367 121,865 123,643
Dilutive effect of stock options and other (in shares) 424 699 375 825
Diluted (in shares) 121,787 124,066 122,240 124,468
Antidilutive stock options and other (in shares) 2,667 1,575 2,667 1,575
v3.26.1
OTHER (INCOME) EXPENSE, NET (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]        
Amortization of trademarks and other intangible assets $ 5 $ 5 $ 15 $ 16
Trust investment (gains) losses, net 3 2 (9) (6)
Net periodic benefit (credit) cost 1 3 2 0
Foreign exchange transaction losses, net 2 (1) 3 2
Income from equity investees 0 0 (2) (3)
Interest income (4) (2) (7) (7)
Other (1) (8) 0 (16)
Total 6 (34) 2 (79)
Cyberattack insurance recoveries   (35)   (70)
August 2023 Cyberattack        
Segment Reporting Information [Line Items]        
Cyberattack insurance recoveries $ 0 (33) $ 0 (65)
Cyberattack insurance recoveries   (35)   (70)
August 2023 Cyberattack | Cost of Products        
Segment Reporting Information [Line Items]        
Cyberattack insurance recoveries   $ (2)   $ (5)
v3.26.1
STOCKHOLDERS' EQUITY - Schedule of Changes in Components of Stockholders’ Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ 35 $ 121 $ 482 $ 492
Beginning balance, common stock (in shares)     122,694,263  
Beginning balance, treasury stock (in shares)     (8,047,198)  
Net earnings 191 191 $ 434 488
Other comprehensive (loss) income 7 5 5 (21)
Dividends to Clorox stockholders (152) (152) (608) (609)
Dividends to noncontrolling interests (5) (4) (12) (11)
Stock-based compensation 15 24 49 64
Other employee stock plan activities 1 5 0 44
Treasury stock purchased     (258) (257)
Ending balance $ 92 $ 190 $ 92 $ 190
Ending balance, common stock (in shares) 120,920,243   120,920,243  
Ending balance, treasury stock (in shares) (9,821,218)   (9,821,218)  
Dividends declared per share (in dollars per share) $ 1.24 $ 1.22 $ 4.96 $ 4.88
Common stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ 131 $ 131 $ 131 $ 131
Beginning balance, common stock (in shares) 130,741,000 130,741,000 130,741,000 130,741,000
Ending balance $ 131 $ 131 $ 131 $ 131
Ending balance, common stock (in shares) 130,741,000 130,741,000 130,741,000 130,741,000
Additional paid-in capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ 1,304 $ 1,287 $ 1,319 $ 1,288
Stock-based compensation 15 24 49 64
Other employee stock plan activities (4) (7) (53) (48)
Ending balance 1,315 1,304 1,315 1,304
Retained earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance 190 68 432 250
Net earnings 187 186 424 478
Dividends to Clorox stockholders (152) (152) (608) (609)
Other employee stock plan activities (2) (3) (25) (20)
Ending balance 223 99 223 99
Treasury stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ (1,591) $ (1,346) $ (1,404) $ (1,186)
Beginning balance, treasury stock (in shares) (9,851,000) (7,591,000) (8,047,000) (6,540,000)
Other employee stock plan activities $ 7 $ 15 $ 78 $ 112
Other employee stock plan activities (in shares) 30,000 101,000 383,000 745,000
Treasury stock purchased     $ (258) $ (257)
Treasury stock purchased (in shares)     (2,157,000) (1,695,000)
Ending balance $ (1,584) $ (1,331) $ (1,584) $ (1,331)
Ending balance, treasury stock (in shares) (9,821,000) (7,490,000) (9,821,000) (7,490,000)
Accumulated other comprehensive net (loss) income        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ (159) $ (181) $ (157) $ (155)
Other comprehensive (loss) income 7 5 5 (21)
Ending balance (152) (176) (152) (176)
Noncontrolling interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance 160 162 161 164
Net earnings 4 5 10 10
Dividends to noncontrolling interests (5) (4) (12) (11)
Ending balance $ 159 $ 163 $ 159 $ 163
v3.26.1
STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance $ 35 $ 121 $ 482 $ 492
Total other comprehensive (loss) income, net of tax 7 5 5 (21)
Ending balance 92 190 92 190
Accumulated other comprehensive net (loss) income        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance (159) (181) (157) (155)
Other comprehensive (loss) income before reclassifications 15 6 20 (15)
Amounts reclassified from Accumulated other comprehensive net (loss) income (3) (2) (12) (6)
Income tax benefit (expense) (5) 1 (3) 0
Total other comprehensive (loss) income, net of tax 7 5 5 (21)
Ending balance (152) (176) (152) (176)
Foreign currency translation adjustments        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance (226) (259) (233) (239)
Other comprehensive (loss) income before reclassifications (4) 6 2 (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 0 0 0
Income tax benefit (expense) 0 1 1 1
Total other comprehensive (loss) income, net of tax (4) 7 3 (13)
Ending balance (230) (252) (230) (252)
Net unrealized gains (losses) on derivatives        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance 69 80 77 85
Other comprehensive (loss) income before reclassifications 19 0 18 (1)
Amounts reclassified from Accumulated other comprehensive net (loss) income (3) (2) (11) (5)
Income tax benefit (expense) (5) 0 (4) (1)
Total other comprehensive (loss) income, net of tax 11 (2) 3 (7)
Ending balance 80 78 80 78
Pension and postretirement benefit adjustments        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance (2) (2) (1) (1)
Other comprehensive (loss) income before reclassifications 0 0 0 0
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 0 (1) (1)
Income tax benefit (expense) 0 0 0 0
Total other comprehensive (loss) income, net of tax 0 0 (1) (1)
Ending balance $ (2) $ (2) $ (2) $ (2)
v3.26.1
OTHER CONTINGENCIES AND GUARANTEES (Details) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2026
Jun. 30, 2025
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 28 $ 27
Letters of credit 18  
Letters of credit, amount outstanding 0  
Alameda County, California Matter    
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 12 12
Remediation period (in years) 30 years  
Maximum undiscounted costs $ 28  
Dickinson County, Michigan Matter    
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 10 $ 10
Remediation period (in years) 30 years  
Percentage of liability for aggregate remediation and associated costs, other than legal fees 24.30%  
v3.26.1
SEGMENT RESULTS - Narrative (Details) - segment
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Concentration Risk [Line Items]        
Number of reportable segments     4  
Revenue from Contract with Customer | Customer Concentration Risk | Walmart Stores, Inc.        
Concentration Risk [Line Items]        
Concentration percentage 28.00% 27.00% 27.00% 26.00%
v3.26.1
SEGMENT RESULTS - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2025
Segment Reporting Information [Line Items]          
Net sales $ 1,670 $ 1,668 $ 4,772 $ 5,116  
Cost of products sold 948 924 2,732 2,827  
Interest income 4 2 7 7  
Interest expense (27) (23) (75) (66)  
Loss on divestiture 0 0 0 (118)  
Cyberattack costs, net of insurance recoveries   35   70  
Digital capabilities and productivity enhancements investment (10) (26) (59) (81)  
Earnings before income taxes 256 254 578 668  
Total assets 6,436   6,436   $ 5,561
(Income) Loss from equity investees included in Other (income) expense, net 0 0 (2) (3)  
Capital expenditures 43 53 121 145  
Depreciation and amortization 58 55 169 162  
Stock-based compensation 15 24 49 64  
GOJO Industries          
Segment Reporting Information [Line Items]          
Acquisition and integration costs (7)   (7)    
Operating Segments          
Segment Reporting Information [Line Items]          
Net sales 1,673 1,668 4,775 5,078  
Segment adjusted EBIT 328 321 851 1,049  
Operating Segments | Health and Wellness          
Segment Reporting Information [Line Items]          
Net sales 629 630 1,837 1,956  
Cost of products sold 319 305 919 928  
Other segment items 152 156 446 431  
Segment adjusted EBIT 158 169 472 597  
Total assets 1,198   1,198   1,217
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0 0  
Capital expenditures 13 15 36 38  
Depreciation and amortization 15 14 44 42  
Stock-based compensation 4 4 12 12  
Operating Segments | Household          
Segment Reporting Information [Line Items]          
Net sales 482 469 1,263 1,362  
Cost of products sold 316 308 858 897  
Other segment items 92 100 282 296  
Segment adjusted EBIT 74 61 123 169  
Total assets 1,085   1,085   1,091
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0 0  
Capital expenditures 15 19 47 58  
Depreciation and amortization 22 20 63 58  
Stock-based compensation 2 3 8 9  
Operating Segments | Lifestyle          
Segment Reporting Information [Line Items]          
Net sales 277 306 843 964  
Cost of products sold 146 154 430 479  
Other segment items 71 92 243 289  
Segment adjusted EBIT 60 60 170 196  
Total assets 1,098   1,098   1,103
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0 0  
Capital expenditures 6 9 18 28  
Depreciation and amortization 6 7 20 18  
Stock-based compensation 2 2 6 6  
Operating Segments | International          
Segment Reporting Information [Line Items]          
Net sales 285 263 832 796  
Cost of products sold 177 162 530 495  
Other segment items 72 70 216 214  
Segment adjusted EBIT 36 31 86 87  
Total assets 1,306   1,306   1,329
(Income) Loss from equity investees included in Other (income) expense, net 0 0 (2) (3)  
Capital expenditures 9 7 17 13  
Depreciation and amortization 11 10 32 31  
Stock-based compensation 1 2 4 5  
Corporate and Other          
Segment Reporting Information [Line Items]          
Net sales (3) 0 (3) 38  
Segment adjusted EBIT (32) (55) (139) (193)  
Total assets 1,749   1,749   $ 821
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0 0  
Capital expenditures 0 3 3 8  
Depreciation and amortization 4 4 10 13  
Stock-based compensation $ 6 $ 13 $ 19 $ 32  
v3.26.1
SEGMENT RESULTS - Schedule of Concentration Percentage (Details) - Revenue from Contract with Customer - Product Concentration Risk
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]        
Concentration percentage 100.00% 100.00% 100.00% 100.00%
Operating Segments | Health and Wellness        
Segment Reporting Information [Line Items]        
Concentration percentage 38.00% 38.00% 38.00% 38.00%
Operating Segments | Health and Wellness | Cleaning        
Segment Reporting Information [Line Items]        
Concentration percentage 33.00% 33.00% 33.00% 33.00%
Operating Segments | Health and Wellness | Professional Products        
Segment Reporting Information [Line Items]        
Concentration percentage 5.00% 5.00% 5.00% 5.00%
Operating Segments | Household        
Segment Reporting Information [Line Items]        
Concentration percentage 29.00% 28.00% 27.00% 27.00%
Operating Segments | Household | Bags and Wraps        
Segment Reporting Information [Line Items]        
Concentration percentage 12.00% 12.00% 12.00% 12.00%
Operating Segments | Household | Cat Litter        
Segment Reporting Information [Line Items]        
Concentration percentage 8.00% 8.00% 9.00% 9.00%
Operating Segments | Household | Grilling        
Segment Reporting Information [Line Items]        
Concentration percentage 9.00% 8.00% 6.00% 6.00%
Operating Segments | Lifestyle        
Segment Reporting Information [Line Items]        
Concentration percentage 16.00% 18.00% 18.00% 19.00%
Operating Segments | Lifestyle | Food        
Segment Reporting Information [Line Items]        
Concentration percentage 11.00% 11.00% 10.00% 11.00%
Operating Segments | Lifestyle | Water Filtration        
Segment Reporting Information [Line Items]        
Concentration percentage 2.00% 4.00% 4.00% 4.00%
Operating Segments | Lifestyle | Natural Personal Care        
Segment Reporting Information [Line Items]        
Concentration percentage 3.00% 3.00% 4.00% 4.00%
Operating Segments | International        
Segment Reporting Information [Line Items]        
Concentration percentage 17.00% 16.00% 17.00% 15.00%
Corporate and Other        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 0.00% 0.00% 1.00%
v3.26.1
SUBSEQUENT EVENTS (Details) - Subsequent Event
$ in Millions
Apr. 01, 2026
USD ($)
Delayed Draw Term Loan (DDTL) | Delayed Draw Term Credit Agreement | Line of Credit  
Subsequent Event [Line Items]  
Proceeds from lines of credit $ 1,250
GOJO Industries  
Subsequent Event [Line Items]  
Purchase consideration $ 2,250